ロード中...
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL
BACKGROUND: Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. METHODS: A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg) in treatment-naive participants with HIV-1 RNA ≥1000 and...
保存先:
| 出版年: | Clin Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5961075/ https://ncbi.nlm.nih.gov/pubmed/29253097 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cix1083 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|